Trial Site Detail
Drug: |
Sunitinib + Regorafenib |
|||
|---|---|---|---|---|
Trial: |
A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Ongoing, but not recruiting |
|||
Dana Farber Cancer Institute450 Brookline Ave |
Principal Investigator: |
Susan George, MD |
|---|---|
Contact: |
617-632-5204 sgeorge2@partners.org |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Dana Farber Cancer Institute Website: |
http://www.dana-farber.org/Research/Clinical-Trials.aspx |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.